Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Kinnear Pharmaceuticals

Pre-clinical

Pre-clinical

Therapeutic Approach

Anti-Infective

This program is studying CSA-131, a synthetic compound that mimics natural compounds in the body that help fight bacterial and fungal infections. CSA-131 aims to inhibit the growth of bacteria and fungi, break down their biofilms -- protective layers that bacteria and fungi form that make them more difficult to kill with anti-infectives -- and ultimately kill these organisms.

Status

Laboratory studies to develop and test this compound are underway.

Sponsor

This program is sponsored by Kinnear Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.



Contact us about Kinnear Pharmaceuticals >